Email UpdatesLiterature Collection
Collection Insights
11K+
References
9K+
Articles
1500+
Grey Literature
4600+
Opioids & SU
The Literature Collection contains over 11,000 references for published and grey literature on the integration of behavioral health and primary care. Learn More
Use the Search feature below to find references for your terms across the entire Literature Collection, or limit your searches by Authors, Keywords, or Titles and by Year, Type, or Topic. View your search results as displayed, or use the options to: Show more references per page; Sort references by Title or Date; and Refine your search criteria. Expand an individual reference to View Details. Full-text access to the literature may be available through a link to PubMed, a DOI, or a URL. References may also be exported for use in bibliographic software (e.g., EndNote, RefWorks, Zotero).
11271 Results
6641
Need for Integrated Behavior Health Model in Primary Care
Type: Journal Article
Year: 2021
Topic(s):
Education & Workforce
See topic collection
, Healthcare Disparities
See topic collection
Reference Links: View the PubMed citation for Need for Integrated Behavior Health Model in Primary Care
6644
Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
Type: Journal Article
Year: 2021
Topic(s):
Education & Workforce
See topic collection
, Opioids & Substance Use
See topic collection
Reference Links:
View the DOI record for Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
View DOI Record
View the PubMed citation for Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada6646
Neighborhood-Level and Spatial Characteristics Associated with Lay Naloxone Reversal Events and Opioid Overdose Deaths
Type: Journal Article
Year: 2016
Publication Place: United States
Abstract: There were over 23,000 opioid overdose deaths in the USA in 2013, and opioid-related mortality is increasing. Increased access to naloxone, particularly through community-based lay naloxone distribution, is a widely supported strategy to reduce opioid overdose mortality; however, little is known about the ecological and spatial patterns of the distribution and utilization of lay naloxone. This study aims to investigate the neighborhood-level correlates and spatial relationships of lay naloxone distribution and utilization and opioid overdose deaths. We determined the locations of lay naloxone distribution sites and the number of unintentional opioid overdose deaths and reported reversal events in San Francisco census tracts (n = 195) from 2010 to 2012. We used Wilcoxon rank-sum tests to compare census tract characteristics across tracts adjacent and not adjacent to distribution sites and multivariable negative binomial regression models to assess the association between census tract characteristics, including distance to the nearest site, and counts of opioid overdose deaths and naloxone reversal events. Three hundred forty-two opioid overdose deaths and 316 overdose reversals with valid location data were included in our analysis. Census tracts including or adjacent to a distribution site had higher income inequality, lower percentage black or African American residents, more drug arrests, higher population density, more overdose deaths, and more reversal events (all p < 0.05). In multivariable analysis, greater distance to the nearest distribution site (up to a distance of 4000 m) was associated with a lower count of Naloxone reversals [incidence rate ratio (IRR) = 0.51 per 500 m increase, 95% CI 0.39-0.67, p < 0.001] but was not significantly associated with opioid overdose deaths. These findings affirm that locating lay naloxone distribution sites in areas with high levels of substance use and overdose risk facilitates reversals of opioid overdoses in those immediate areas but suggests that alternative delivery methods may be necessary to reach individuals in other areas with less concentrated risk.
Topic(s):
Opioids & Substance Use
See topic collection
Reference Links:
View the DOI record for Neighborhood-Level and Spatial Characteristics Associated with Lay Naloxone Reversal Events and Opioid Overdose Deaths
View DOI Record
View the PubMed citation for Neighborhood-Level and Spatial Characteristics Associated with Lay Naloxone Reversal Events and Opioid Overdose Deaths6648
Neonatal Abstinence Syndrome: Advances in Diagnosis and Treatment
Type: Journal Article
Year: 2018
Abstract: IMPORTANCE: Neonatal abstinence syndrome, which occurs as a result of in utero opioid exposure, affects between 6.0 and 20 newborns per 1000 live US births. There is substantial variability in how neonatal abstinence syndrome is diagnosed and managed. OBJECTIVE: To summarize key studies examining the diagnosis and management (both pharmacologic and nonpharmacologic) of neonatal abstinence syndrome published during the past 10 years. EVIDENCE REVIEW: PubMed, Web of Science, and CINAHL were searched for articles published between July 1, 2007, and December 31, 2017. Abstracts were screened and included in the review if they pertained to neonatal abstinence syndrome diagnosis or management and were judged by the authors to be clinical trials, cohort studies, or case series. FINDINGS: A total of 53 articles were included in the review, including 9 randomized clinical trials, 35 cohort studies, 1 cross-sectional study, and 8 case series-representing a total of 11?905 unique opioid-exposed mother-infant dyads. Thirteen studies were identified that evaluated established or novel neonatal abstinence syndrome assessment methods, such as brief neonatal abstinence syndrome assessment scales or novel objective physiologic measures to predict withdrawal. None of the new techniques that measure infant physiologic parameters are routinely used in clinical practice. The most substantial number of studies of neonatal abstinence syndrome management pertain to nonpharmacologic care-specifically, interventions that promote breastfeeding or encourage parents to room-in with their newborns. Although these nonpharmacologic interventions appear to decrease the need for pharmacologic treatment and result in shorter hospitalizations, the interventions are heterogeneous and there are no high-quality clinical trials to support them. Regarding pharmacologic interventions, only 5 randomized clinical trials with prespecified sample size calculations (4 infant, 1 maternal treatment) have been published. Each of these trials was small (from?26 to 131 participants) and tested different therapies, limiting the extent to which results can be aggregated. There is insufficient evidence to support an association between any diagnostic or treatment approach and differential neurodevelopmental outcomes among infants with neonatal abstinence syndrome. CONCLUSIONS AND RELEVANCE: Evidence pertaining to the optimal diagnosis and treatment strategies for neonatal abstinence syndrome is based on small or low-quality studies that focus on intermediate outcomes, such as need for pharmacologic treatment or length of hospital stay. Clinical trials are needed to evaluate health and neurodevelopmental outcomes associated with objective diagnostic approaches as well as pharmacologic and nonpharmacologic treatment modalities.
Topic(s):
Opioids & Substance Use
See topic collection
Reference Links:
View the DOI record for Neonatal Abstinence Syndrome: Advances in Diagnosis and Treatment
View DOI Record
View the PubMed citation for Neonatal Abstinence Syndrome: Advances in Diagnosis and Treatment6650
Neonatal abstinence syndrome: Neurobehavior at 6 weeks of age in infants with or without pharmacological treatment for withdrawal
Type: Journal Article
Year: 2017
Publication Place: United States
Topic(s):
Healthcare Disparities
See topic collection
, Opioids & Substance Use
See topic collection
6651
Neonatal Abstinence Syndrome: Presentation and Treatment Considerations
Type: Journal Article
Year: 2016
Abstract: This clinical case conference discusses the treatment of a pregnant woman with opioid use disorder in a comprehensive care program that includes buprenorphine pharmacotherapy. The presentation summarizes common experiences that pregnant women who receive buprenorphine pharmacotherapy face, and also what their prenatally opioid-exposed children confront in the immediate postpartum period. It describes the elements of a successful comprehensive care model and corollary neonatal abstinence syndrome treatment regimen. Expert commentary is included on issues that arise in the buprenorphine induction and maintenance throughout the prenatal and postpartum periods and in the treatment of co-occurring mental health problems during both the prenatal and postpartum periods, particularly the treatment of depression. There is also expert commentary on the care of opioid-exposed neonates, with attention to the treatment for neonatal abstinence syndrome.
Topic(s):
Opioids & Substance Use
See topic collection
, Healthcare Disparities
See topic collection
View the PubMed citation for Neonatal Abstinence Syndrome: Presentation and Treatment Considerations
Reference Links:
View the DOI record for Neonatal Abstinence Syndrome: Presentation and Treatment Considerations
View DOI Record
View the PubMed citation for Neonatal Abstinence Syndrome: Presentation and Treatment Considerations6652
Neonatal Abstinence Syndrome: Prevention, Recognition, Treatment, and Follow-up
Type: Journal Article
Year: 2021
Publication Place: United States
Topic(s):
Education & Workforce
See topic collection
, Healthcare Disparities
See topic collection
, Opioids & Substance Use
See topic collection
Reference Links: View the PubMed citation for Neonatal Abstinence Syndrome: Prevention, Recognition, Treatment, and Follow-up
6653
Neonatal Abstinence Syndrome: Twelve Years of Experience at a Regional Referral Center
Type: Journal Article
Year: 2017
Publication Place: Germany
Topic(s):
Healthcare Disparities
See topic collection
, Opioids & Substance Use
See topic collection
Reference Links:
View the DOI record for Neonatal Abstinence Syndrome: Twelve Years of Experience at a Regional Referral Center
View DOI Record
View the PubMed citation for Neonatal Abstinence Syndrome: Twelve Years of Experience at a Regional Referral Center6655
Neonatal neurobehavior effects following buprenorphine versus methadone exposure
Type: Journal Article
Year: 2012
Publication Place: England
Topic(s):
Opioids & Substance Use
See topic collection
, Healthcare Disparities
See topic collection
Reference Links:
View the DOI record for Neonatal neurobehavior effects following buprenorphine versus methadone exposure
View DOI Record
View the PubMed citation for Neonatal neurobehavior effects following buprenorphine versus methadone exposure6660
Neurobiologic Advances from the Brain Disease Model of Addiction
Type: Journal Article
Year: 2016
Publication Place: United States
Abstract: This article reviews scientific advances in the prevention and treatment of substance-use disorder and related developments in public policy.
Topic(s):
Opioids & Substance Use
See topic collection
, Healthcare Policy
See topic collection
Reference Links:
View the DOI record for Neurobiologic Advances from the Brain Disease Model of Addiction
View DOI Record
View the PubMed citation for Neurobiologic Advances from the Brain Disease Model of Addiction